UNSPSC 51241108: Echothiophate or ecothiopate

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C9H23NO3PS.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BA9QH3P00T, chemically known as s-ester of (2-mercaptoethyl)trimethylammonium iodide with o,o-diethyl phosphorothioate but generally known as echothiophate iodide, which bears US NIH Compound Identifier 10547. European Medicines Agency schedules Ecothiopate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01856MIG.

UNSPSC 51241108 Echothiophate or ecothiopate is a Commodity code for pharmaceutical active ingredients and finished pharmaceutical products sourced through state and local cooperative purchasing agreements. State and local governments procure echothiophate—a cholinesterase inhibitor used in ophthalmologic treatments—as part of broader multi-source generic pharmaceutical contracts that serve health departments, correctional facilities, clinical care centers, and other public health operations. The single recent opportunity on record shows state and local buyers acquiring echothiophate and related generic pharmaceuticals through cooperative purchasing vehicles with strict manufacturer compliance requirements, including current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and FDA regulatory adherence. Issuing bodies include state departments and participating jurisdictions within cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the identified buyer for the most recent solicitation.

The Minnesota Department of Administration issued a Request for Proposal on January 20, 2026 under solicitation S1070000015802 to establish multiple manufacturer contracts for generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 response deadline. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet stringent administrative and technical requirements including $5,000,000 commercial general liability insurance, EDI capability, and pricing flexibility through flat-price or WAC-minus formats. The resulting contracts are effective July 1, 2026 with a two-year initial term, and vendors incur a 3 percent administrative fee on all purchases with performance penalties ranging from $200 to $1,500 per violation. Geographic activity is concentrated in the upper Midwest and Pacific Northwest, with Minnesota and Oregon participating in the cooperative arrangement; no other recent state and local opportunities for echothiophate are present in the available record.